Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap - LARVOL DELTA

Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis (clinicaltrials.gov) - P4 | N=20 | Not yet recruiting | Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

New P4 trial • Candidiasis

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. (PubMed, Antimicrob Agents Chemother) - "In conclusion, our in vitro model highlights the antibiofilm activity of novel antifungals against major Candida species, revealing significant differences in efficacy among species. MNGX demonstrated the highest activity, underscoring its potential as a promising candidate for the treatment of biofilm-related infections."

Journal • Infectious Disease

In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium. (PubMed, Antimicrob Agents Chemother) - "In this article, we assessed the in vitro activity of the novel antifungals olorofim, manogepix, rezafungin, and ibrexafungerp, as well as the established but nonstandard drugs, natamycin and terbinafine, against a large set of molecularly identified clinical Fusarium isolates via EUCAST microdilution. Furthermore, we report specific susceptibilities for terbinafine against FDSC, FFSC, and FOSC species. These findings of complex- and species-specific olorofim and terbinafine in vitro susceptibilities highlight the need for diagnostics below genus level."

Journal • Preclinical • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Early use of the novel antifungal rezafungin: a case series and literature review. (PubMed, J Antimicrob Chemother) - "Early use of rezafungin at our centre and in the international literature suggests it is a well-tolerated, convenient and useful addition to the antifungal armamentarium, particularly in the outpatient setting."

Journal • Candidiasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin. (PubMed, IDCases) - "Her isolate showed increasing minimum inhibitory concentrations (MIC) to various antifungals with higher MICs to azoles, including resistance to fluconazole, resulting in limited treatment options. She had affliction of her prosthetic pulmonic valve with C. glabrata and was treated with the second-generation echinocandin, rezafungin, for six months. This case illustrates the tolerability profile of long-term treatment with rezafungin."

Journal • Candidiasis • Cardiovascular • Heart Failure • Infectious Disease

Rezafungin for suppressive therapy of Candida auris in a patient with a left ventricular assist device (LVAD). (PubMed, IDCases) - "The patient was originally on indefinite micafungin therapy, but was eventually switched to once-weekly rezafungin as this was felt to be safer, easier, and more convenient for the patient. Though the patient did develop a breakthrough C. auris bloodstream infection while on rezafungin therapy, his infection was well-controlled for a little over 4 months, which prevented any C. auris-related hospital admissions during that time period. This case represents the first example of rezafungin being used for an LVAD-associated C. auris infection."

Journal • Candidiasis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease

Activity of rezafungin against Candida auris. (PubMed, J Antimicrob Chemother) - "Although there is currently a dearth of data on the therapeutic activity of rezafungin against C. auris, it is reasonable that rezafungin may be a viable choice for treating candidemia and invasive candidiasis caused by C. auris. Further clinical investigations are necessary."

Journal • Candidiasis • Infectious Disease

Successful rezafungin treatment of an azole-resistant Candida parapsilosis vascular graft infection. (PubMed, Rev Esp Quimioter) - No abstract available

Journal • Infectious Disease

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age (clinicaltrials.gov) - P1 | N=32 | Terminated | Sponsor: Mundipharma Research Limited | Trial completion date: Dec 2027 ➔ Oct 2024 | Suspended ➔ Terminated | Trial primary completion date: Mar 2027 ➔ May 2024; The study had initially anticipated dosing of the first cohort within 4-9 months of activation; however the study faced significant challenges in recruitment. In order to adhere to the previously approved PIP plan, the study could not be redesigned.

Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Pediatrics

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Mundipharma Research Limited | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Oct 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Pneumonia • Respiratory Diseases

Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin. (PubMed, Eur J Clin Microbiol Infect Dis) - "In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin, a new echinocandin suitable for weekly outpatient administration. This case illustrates the first documented use of rezafungin in an outpatient setting for C. albicans spondylodiscitis, demonstrating its potential in managing complex fungal infections."

Journal • Candidiasis • Infectious Disease

Successful use of rezafungin for treatment of Candida albicans spondylodiscitis (ESCMID Global 2025) - No abstract available

Clinical outcomes with rezafungin or caspofungin in adults with invasive infections due to non-albicans Candida: pooled analysis from STRIVE and ReSTORE trials (including extension phase data) (ESCMID Global 2025) - No abstract available

Clinical data • Retrospective data • Infectious Disease

Study design: Phase 2, multicentre, open-label, randomised, active-controlled trial to evaluate the efficacy and safety of rezafungin adjunctive therapy in HIV-associated Pneumocystis jirovecii pneumonia (ESCMID Global 2025) - No abstract available

Clinical • P2 data • Human Immunodeficiency Virus • Infectious Disease • Pneumonia

Real-world experience with rezafungin: a novel long-acting echinocandin (ESCMID Global 2025) - No abstract available

Clinical • Real-world • Real-world evidence

Effect of rezafungin against biofilm of Candida parapsilosis fluconazole-resistant isolates (ESCMID Global 2025) - No abstract available

Evaluation of rezafungin on the thermo scientific sensititre YeastOne panel (ESCMID Global 2025) - No abstract available

In vitro activity of rezafungin against antifungal-resistant Candida spp isolates: loss of activity against C. glabrata isolates harbouring S663 and delF659 substitutions (ESCMID Global 2025) - No abstract available

Preclinical

In vitro activitiy of rezafungin in comparison with anidulafungin and caspofungin against invasive fungal isolates in China, 2017-2022 (ESCMID Global 2025) - No abstract available

Preclinical

Rezafungin showed high in vitro activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024 (ESCMID Global 2025) - No abstract available

Preclinical

Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis (ESCMID Global 2025) - No abstract available

Retrospective data • Candidiasis

A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against Candida auris with EUCAST broth microdilution reference methodology (ESCMID Global 2025) - No abstract available

Clinical

Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay (ESCMID Global 2025) - No abstract available

Disseminated infection with Candida dubliniensis after ravulizumab and treatment with rezafungin - a case report. (PubMed, J Mycol Med) - No abstract available

Journal • Infectious Disease

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods. (PubMed, JAC Antimicrob Resist) - "The compounds with the greatest in vitro activity, as indicated by the lowest geometric mean MIC (GM), were manogepix (GM: 0.01), isavuconazole (GM: 0.05) and rezafungin (GM: 0.03-0.07). The overall essential agreement (EA) (within ±0 to ±2 2-fold dilutions) between the reference methods, EUCAST and CLSI, was 95%, with results ranging from 82% (ibrexafungerp) to 100% (amphotericin B, anidulafungin, fluconazole, 5-flucytosine and micafungin)...However, the differences in EA, particularly for ibrexafungerp and 5-flucytosine, highlight the importance of continued evaluation of these methodologies to ensure consistency. Given that antifungal susceptibility testing plays a critical role in treatment decisions, understanding these variations is essential to prevent potential misclassification of susceptibility profiles, which could impact clinical outcomes."

Journal